Fezolinetant
Moderate-to-severe vasomotor symptoms (hot flashes) of menopause
- CAS No.
- 1629229-37-3
- Indication Class
- Urology / Women's Health
- Patent Expiry
- To be assessed
- Therapeutic Area
- Women's Health
- Target / Mechanism
- TACR3
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 6 key intermediates available
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| (R)-3-Methylpiperazin-2-one | 922178-61-8 | — | |
| (R)-4-(2,4-diMethoxybenzyl)-3-Methylpiperazin-2-one | 1383146-20-0 | — | |
| 3-Methyl-[1,2,4]thiadiazole-5-carboxylic acid ethyl ester | 76162-56-6 | — | |
| 3-Methyl-1,2,4-thiadiazole-5-carbohydrazide | 1375066-73-1 | — | |
| 3-Methyl-piperazin-2-one | 23936-11-0 | — | |
| 5-bromo-3-methyl-1,2,4-thiadiazole | 54681-68-4 | — |
Listing Logic · Why It's Worth Listing
The first approved non-hormonal therapy for menopausal hot flashes, with broad scope to replace hormone therapy, a large and long-unmet patient population.
Women's Health · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
6 key intermediates available; scale-up and cost control manageable
Product Description
Fezolinetant is the first FDA-approved medication in a new class of drugs for treating moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause. It represents a significant advancement as a non-hormonal treatment option for women seeking relief from these common and often disruptive symptoms.
Supply source: Unibest · Fezolinetant, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.